In preclinical models of lung, breast, and colon cancer, in vivo treatment with the PI3K-α/δ inhibitor AZD8835 and the PI3K-δ inhibitor idelalisib favorably increased CD8+ TIL/Treg ratios by ~2-fold (36). This evidence concerns the gene CD8A and colonic neoplasm.